Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Blockhead12-16

Viridian Therapeutics (VRDN) stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell. ↑ X How To Buy Stocks: Swing Trading ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491613359?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2018/04/stock-biotech-16-adobe-150x150.jpg","is_english":true,"pubTime":"2024-12-16 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491613359","market":"sg","top_or_hot":-1,"title":"Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease","media":"Blockhead","content":"<div>\n<p>Viridian Therapeutics (VRDN) stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: Swing Trading ...</p>\n\n<a href=\"https://www.investors.com/news/technology/viridian-therapeutics-chronic-thyroid-eye-diease-amgen-tepezza/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/viridian-therapeutics-chronic-thyroid-eye-diease-amgen-tepezza/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viridian Therapeutics (VRDN) stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: Swing Trading ...</p>\n\n<a href=\"https://www.investors.com/news/technology/viridian-therapeutics-chronic-thyroid-eye-diease-amgen-tepezza/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/viridian-therapeutics-chronic-thyroid-eye-diease-amgen-tepezza/","article_id":"2491613359","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/04/stock-biotech-16-adobe-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491613359","pubTimestamp":1734359322,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4599":"减肥药","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","AMGN":"安进","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4566":"资本集团","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0058720904.USD":"联博国际健康护理基金A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LENZ":"Therapeutics","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","VRDN":"Viridian Therapeutics, Inc.","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4581":"高盛持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist"},"translate_title":"Viridian Therapeutics在甲状腺眼病领域击败安进后股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRDN":1,"AMGN":1,"LENZ":1},"content_text":"Viridian Therapeutics (VRDN) stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: Swing Trading Vs. Position Trading\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: Swing Trading Vs. Position Trading\n\n\n\n\nAfter 15 weeks, 56% of patients saw an improvement in proptosis, or eye swelling. This beat out the 8% response rate in the placebo group and was in line with expectations for a 52% to 62% response rate, RBC Capital Markets analyst Gregory Renza said in a report.\nFurther, 56% of patients who received Viridian's veligrotug had improvement in diplopia, or double vision. Nearly a third of patients, 32%, experienced complete resolution of diplopia. In comparison just 25% of placebo patients showed any diplopia improvement and 14% has complete resolution.\nThe results compare favorably to Amgen's (AMGN) Tepezza, analysts said. In clinical testing, Tepezza didn't lead to any improvement in diplopia.\n\"Meaningful improvement in diplopia adds a key differentiator to Veli' over Tepezza, which we believe will shift the narrative from achieving an as-good profile to having a superior profile, in chronic TED patients,\" Renza said.\nIn premarket trades on the stock market today, Viridian Therapeutics shares surged more than 18% to 21.08. That put shares within striking distance of their 50-day moving average, according to MarketSurge.\nMore to follow.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nNeurocrine Wins FDA Approval For Genetic Disorder Drug\nBattle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?\nOptions Trading: How To Start Using Options, How To Manage Risk\nSee Stocks On The List Of Leaders Near A Buy Point\nFind Today's Best Growth Stocks To Watch With IBD 50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491613359"}